Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SYBX 
Synlogic Inc (SYBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SYBX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.88% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.97M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 7074 | Beta 0.72 | 52 Weeks Range 1.15 - 1.96 | Updated Date 04/1/2025 |
52 Weeks Range 1.15 - 1.96 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.92 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.1 | Actual 0.85 |
Profitability
Profit Margin - | Operating Margin (TTM) -197212.5% |
Management Effectiveness
Return on Assets (TTM) -20.68% | Return on Equity (TTM) -102.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4356825 | Price to Sales(TTM) 1871.38 |
Enterprise Value -4356825 | Price to Sales(TTM) 1871.38 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA 0.18 | Shares Outstanding 11696100 | Shares Floating 2235477 |
Shares Outstanding 11696100 | Shares Floating 2235477 | ||
Percent Insiders 11.79 | Percent Institutions 64.61 |
Analyst Ratings
Rating 3 | Target Price 1 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Synlogic Inc
Company Overview
History and Background
Synlogic Inc. was founded in 2013 and is a clinical-stage biopharmaceutical company pioneering the development of Synthetic Biotic medicines for metabolic and immunological diseases. They focus on leveraging engineered bacteria to perform specific functions within the body.
Core Business Areas
- Synthetic Biotic Medicines: Synlogic focuses on developing proprietary Synthetic Biotic medicines, engineered microbial organisms designed to address metabolic and immunological disorders.
- Drug Discovery and Development: The company engages in the discovery, development, and manufacturing of these novel therapeutics.
Leadership and Structure
Aoife Brennan, M.B. Ch.B., Ph.D. serves as President and Chief Executive Officer. The company has a typical biotech organizational structure with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- SYNB1618 (Phenylketonuria - PKU): SYNB1618 is an investigational Synthetic Biotic medicine for the treatment of phenylketonuria (PKU). It is designed to break down phenylalanine (Phe) in the GI tract, reducing levels of Phe in the blood. Currently in clinical trials. Market share is not applicable at this stage due to the product being in clinical development. Competitors in PKU treatment include BioMarin Pharmaceutical (BMNM) with Kuvan and Palynziq.
- SYNB1934 (Homocystinuria - HCU): SYNB1934 is an investigational Synthetic Biotic medicine for the treatment of homocystinuria (HCU). It is designed to address elevated homocysteine levels. Currently in clinical trials. Market share is not applicable at this stage due to the product being in clinical development. No direct competitors currently.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with a focus on developing innovative therapies for unmet medical needs. The segment of synthetic biology-based therapeutics is emerging and growing.
Positioning
Synlogic is positioned as a pioneer in the field of Synthetic Biotic medicines. Their competitive advantage lies in their proprietary technology platform and focus on engineering bacteria for therapeutic purposes.
Total Addressable Market (TAM)
The TAM for metabolic and immunological diseases is substantial, estimated in the billions of dollars. Synlogic's positioning is aimed at capturing a portion of this market by addressing specific diseases with unmet needs.
Upturn SWOT Analysis
Strengths
- Novel Synthetic Biotic platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Early stage clinical development
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new disease areas
- Positive clinical trial results
- Orphan drug designations
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
- Financial constraints
Competitors and Market Share
Key Competitors
- BMNM
- CRL
- ADVM
Competitive Landscape
Synlogic faces competition from established pharmaceutical companies and other biotechnology firms. Their advantage lies in the novelty of their approach, but they face the challenges of clinical development and commercialization.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial progress and partnerships. Has been volatile.
Future Projections: Future growth is highly dependent on clinical trial success and potential partnerships. Analyst projections are speculative.
Recent Initiatives: Focus on advancing clinical trials for SYNB1618 and SYNB1934, and exploring new indications for their Synthetic Biotic platform.
Summary
Synlogic is an early-stage biotech company with a promising Synthetic Biotic platform. Their future is highly dependent on successful clinical trial outcomes and securing partnerships. The company's current focus is on advancing their clinical pipeline, but they face the risks associated with drug development and regulatory approval. Financial performance will be closely watched.
Similar Companies
ADVM
Adverum Biotechnologies Inc
ADVM
Adverum Biotechnologies Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
ZYME
Zymeworks Inc. Common Stock
ZYME
Zymeworks Inc. Common Stock
Sources and Disclaimers
Data Sources:
- Synlogic Inc. Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synlogic Inc
Exchange NASDAQ | Headquaters Winchester, MA, United States | ||
IPO Launch date 2015-10-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.synlogictx.com |
Full time employees 1 | Website https://www.synlogictx.com | ||
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.